326 related articles for article (PubMed ID: 33877518)
1. Emerging Role of PD-1 in the Central Nervous System and Brain Diseases.
Zhao J; Roberts A; Wang Z; Savage J; Ji RR
Neurosci Bull; 2021 Aug; 37(8):1188-1202. PubMed ID: 33877518
[TBL] [Abstract][Full Text] [Related]
2. Regulation of Neuroinflammation through Programed Death-1/Programed Death Ligand Signaling in Neurological Disorders.
Zhao S; Li F; Leak RK; Chen J; Hu X
Front Cell Neurosci; 2014; 8():271. PubMed ID: 25232304
[TBL] [Abstract][Full Text] [Related]
3. Anti-PD-1 cancer immunotherapy induces central nervous system immune-related adverse events by microglia activation.
Vinnakota JM; Adams RC; Athanassopoulos D; Schmidt D; Biavasco F; Zähringer A; Erny D; Schwabenland M; Langenbach M; Wenger V; Salié H; Cook J; Mossad O; Andrieux G; Dersch R; Rauer S; Duquesne S; Monaco G; Wolf P; Blank T; Häne P; Greter M; Becher B; Henneke P; Pfeifer D; Blazar BR; Duyster J; Boerries M; Köhler N; Chhatbar CM; Bengsch B; Prinz M; Zeiser R
Sci Transl Med; 2024 Jun; 16(751):eadj9672. PubMed ID: 38865481
[TBL] [Abstract][Full Text] [Related]
4. Glial Cell Expression of PD-L1.
Chauhan P; Lokensgard JR
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30987269
[TBL] [Abstract][Full Text] [Related]
5. Control of glial immune function by neurons.
Neumann H
Glia; 2001 Nov; 36(2):191-9. PubMed ID: 11596127
[TBL] [Abstract][Full Text] [Related]
6. The majority of infiltrating CD8 T lymphocytes in multiple sclerosis lesions is insensitive to enhanced PD-L1 levels on CNS cells.
Pittet CL; Newcombe J; Antel JP; Arbour N
Glia; 2011 May; 59(5):841-56. PubMed ID: 21360758
[TBL] [Abstract][Full Text] [Related]
7. PD-1/PD-Ls: A New Target for Regulating Immunopathogenesis in Central Nervous System Disorders.
Wu J; Yu Z; Chen G
Curr Drug Deliv; 2017 Sep; 14(6):791-796. PubMed ID: 27889994
[TBL] [Abstract][Full Text] [Related]
8. The role of interleukin-6 in the expression of PD-1 and PDL-1 on central nervous system cells following infection with Theiler's murine encephalomyelitis virus.
Jin YH; Hou W; Kang HS; Koh CS; Kim BS
J Virol; 2013 Nov; 87(21):11538-51. PubMed ID: 23966393
[TBL] [Abstract][Full Text] [Related]
9. PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression.
Filippone A; Lanza M; Mannino D; Raciti G; Colarossi C; Sciacca D; Cuzzocrea S; Paterniti I
Cancer Immunol Immunother; 2022 Sep; 71(9):2067-2075. PubMed ID: 35092481
[TBL] [Abstract][Full Text] [Related]
10. Neuronal injury in chronic CNS inflammation.
Zindler E; Zipp F
Best Pract Res Clin Anaesthesiol; 2010 Dec; 24(4):551-62. PubMed ID: 21619866
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract][Full Text] [Related]
12. Glial Cells: Role of the Immune Response in Ischemic Stroke.
Xu S; Lu J; Shao A; Zhang JH; Zhang J
Front Immunol; 2020; 11():294. PubMed ID: 32174916
[TBL] [Abstract][Full Text] [Related]
13. Programmed death-1 pathway limits central nervous system inflammation and neurologic deficits in murine experimental stroke.
Ren X; Akiyoshi K; Vandenbark AA; Hurn PD; Offner H
Stroke; 2011 Sep; 42(9):2578-83. PubMed ID: 21737801
[TBL] [Abstract][Full Text] [Related]
14. Decoding Mast Cell-Microglia Communication in Neurodegenerative Diseases.
Sandhu JK; Kulka M
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499208
[TBL] [Abstract][Full Text] [Related]
15. Application of PD-1 Blockade in Cancer Immunotherapy.
Wu X; Gu Z; Chen Y; Chen B; Chen W; Weng L; Liu X
Comput Struct Biotechnol J; 2019; 17():661-674. PubMed ID: 31205619
[TBL] [Abstract][Full Text] [Related]
16. Activation and control of CNS innate immune responses in health and diseases: a balancing act finely tuned by neuroimmune regulators (NIReg).
Hoarau JJ; Krejbich-Trotot P; Jaffar-Bandjee MC; Das T; Thon-Hon GV; Kumar S; Neal JW; Gasque P
CNS Neurol Disord Drug Targets; 2011 Feb; 10(1):25-43. PubMed ID: 21143144
[TBL] [Abstract][Full Text] [Related]
17. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.
Levite M
J Neural Transm (Vienna); 2014 Aug; 121(8):1029-75. PubMed ID: 25081016
[TBL] [Abstract][Full Text] [Related]
18. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis.
Pittet CL; Newcombe J; Prat A; Arbour N
J Neuroinflammation; 2011 Nov; 8():155. PubMed ID: 22067141
[TBL] [Abstract][Full Text] [Related]
19. Microglia and mast cells: two tracks on the road to neuroinflammation.
Skaper SD; Giusti P; Facci L
FASEB J; 2012 Aug; 26(8):3103-17. PubMed ID: 22516295
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
